" class="no-js "lang="en-US"> Amphista Therapeutics - Medtech Alert
Friday, March 29, 2024
Amphista Therapeutics | Pharmtech Focus

Amphista Therapeutics

About Amphista Therapeutics

Amphista Therapeutics

At Amphista Therapeutics we are developing drugs to bring life-changing medicines to patients. Powered by transformational science we are advancing beyond traditional degrader approaches.

Amphista Therapeutics is an exciting spin out company founded by Advent Life Sciences and built on groundbreaking science from the laboratory of Professor Alessio Ciulli (University of Dundee), a world leader in the field of targeted protein degradation.

Targeted protein degradation (TPD) hijacks the cell’s degradation machinery to modulate abundance of proteins that are responsible for disease progression. Our approach to protein degradation differentiates from traditional TPD technologies and is being developed to treat diseases with high unmet need.

Related Story

Amphista Therapeutics Appoints Dr Martin Pass as CDO

December 6 2021

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the […]

Amphista Therapeutics Appoints CBO, Beverley Carr

November 1 2021

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the […]

Amphista Therapeutics Appoints New Chairman, Joshua T. Brumm

September 21 2021

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the […]

Amphista Therapeutics Expands Research Team by Appointing Martin O'Rourke as Head of Drug Discovery and James Osborne as Director of Chemistry

June 28 2021

Amphista Therapeutics, a Targeted Protein Degradation (TPD) biopharmaceutical company creating first-in-class cancer therapeutics that harness […]